BioTime to Announce Fourth Quarter and Fiscal 2017 Results on March 15, 2018

On March 5, 2018 BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, reported that it will release fourth quarter and fiscal 2017 financial and operating results on Thursday, March 15, 2018, after the close of the U.S. financial markets (Press release, BioTime, MAR 5, 2018, View Source;p=RssLanding&cat=news&id=2336117 [SID1234524386]). The Company will host a conference call and webcast on Thursday, March 15, 2018, at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time to discuss the results and recent corporate developments.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call dial-in number in the U.S./Canada is 1-866-888-8633. For international participants outside the U.S./Canada, the dial-in number is 1-636-812-6629. For all callers, please refer to Conference ID number 5878807. The live webcast can be accessed on the "Events & Presentations" page of the "Investors & Media" section on the company’s website.

A replay of the conference call will be available for seven business days beginning about two hours after the conclusion of the live call, by calling toll-free from U.S./Canada: 1-855-859-2056; international callers dial 1-404-537-3406. Use the Conference ID number 5878807. Additionally, the archived webcast will be available on the "Events & Presentations" page of the "Investors & Media" section on the company’s website.

Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2018 After Market Close on March 12, 2018

On March 5, 2018 Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, reported that financial results for the third quarter of fiscal year 2018 ended January 31, 2018 on March 12, 2018 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time) (Press release, Avid Bioservices, MAR 5, 2018, View Source [SID1234524385]). Avid’s senior management will discuss financial results for the third quarter and review recent corporate developments.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To listen to the live webcast, or access the archived webcast, please visit: View Source

To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Avid Bioservices call.

Array BioPharma To Present At The Cowen 38th Annual Healthcare Conference

On March 5, 2018 Array BioPharma Inc. (Nasdaq: ARRY) reported that its Chief Executive Officer, Ron Squarer, will speak at the Cowen 38th Annual Healthcare Conference in Boston (Press release, Array BioPharma, MAR 5, 2018, View Source;p=RssLanding&cat=news&id=2336279 [SID1234524384]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The public is welcome to participate in the conference through a webcast on the Array BioPharma website.

Event:

Cowen 38th Annual Healthcare Conference

Presenter:

Ron Squarer, Chief Executive Officer, Array BioPharma

Date:

Monday, March 12, 2018

Time:

11:20 a.m. Eastern Time

Webcast:

http://wsw.com/webcast/cowen46/arry/

ArQule to Present at the 30th Annual Roth Conference on March 12, 2018

On March 5,2018 ArQule, Inc. (Nasdaq: ARQL) reported that Paolo Pucci, Chief Executive Officer, will present at the 30th Annual Roth Conference on March 12th, 2018, at 5:00 p.m. PT at the Ritz-Carlton in Dana Point, California the 30th Annual Roth Conference on March 12th, 2018, at 5:00 p.m. PT at the Ritz-Carlton in Dana Point, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

You can access the live webcast of the presentation via the "Investors & Media" section of our website, www.arqule.com, under "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation

ArQule Reports Fourth Quarter and Full Year 2017 Financial Results

On March 5, 2018 ArQule, Inc. (Nasdaq: ARQL) reported that Paolo Pucci, Chief Executive Officer, will present at the 30th Annual Roth Conference on March 12th, 2018, at 5:00 p.m. PT at the Ritz-Carlton in Dana Point, California (Press release, ArQule, MAR 5, 2018, View Source [SID1234524382]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

You can access the live webcast of the presentation via the "Investors & Media" section of our website, www.arqule.com, under "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation.